Prelude Capital Management, LLC Jounce Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $41,440 - $113,516	-14,800 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$6.01 - $8.54 $12,020 - $17,080	2,000 Added 15.63%	14,800 $100,000
Q4 2021 Feb 14, 2022	BUY	$7.11 - $9.64 $91,008 - $123,392	12,800 New	12,800 $107,000
Q3 2021 Nov 15, 2021	SELL	$5.04 - $8.73 $57,456 - $99,522	-11,400 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $75,012 - $121,524	11,400 New	11,400 $78,000
Q4 2020 Feb 16, 2021	SELL	$6.37 - $10.33 $1,274 - $2,066	-200 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $916 - $2,190	200 New	200 $2,000
Q1 2020 May 15, 2020	SELL	$2.91 - $8.7 $12,513 - $37,410	-4,300 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$2.81 - $9.21 $12,083 - $39,603	4,300 New	4,300 $38,000
Q4 2018 Feb 14, 2019	SELL	$2.69 - $6.71 $8,858 - $22,096	-3,293 Closed	0 $0
Q3 2018 Nov 14, 2018	BUY	$6.5 - $8.37 $6,454 - $8,311	993 Added 43.17%	3,293 $21,000
Q2 2018 Aug 14, 2018	BUY	$7.27 - $21.88 $16,721 - $50,324	2,300 New	2,300 $18,000

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.